BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 36973285)

  • 1. Rewired m
    Xu A; Liu M; Huang MF; Zhang Y; Hu R; Gingold JA; Liu Y; Zhu D; Chien CS; Wang WC; Liao Z; Yuan F; Hsu CW; Tu J; Yu Y; Rosen T; Xiong F; Jia P; Yang YP; Bazer DA; Chen YW; Li W; Huff CD; Zhu JJ; Aguilo F; Chiou SH; Boles NC; Lai CC; Hung MC; Zhao Z; Van Nostrand EL; Zhao R; Lee DF
    Nat Commun; 2023 Mar; 14(1):1694. PubMed ID: 36973285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations.
    Liu PK; Kraus E; Wu TA; Strong LC; Tainsky MA
    Oncogene; 1996 Jun; 12(11):2267-78. PubMed ID: 8649766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukemic and non-leukemic lymphocytes from patients with Li Fraumeni syndrome demonstrate loss of p53 function, Bcl-2 family dysregulation and intrinsic resistance to conventional chemotherapeutic drugs but not flavopiridol.
    Pepper C; Thomas A; Hoy T; Tighe J; Culligan D; Fegan C; Bentley P
    Cell Cycle; 2003; 2(1):53-8. PubMed ID: 12695689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
    Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
    Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation.
    Rivlin N; Katz S; Doody M; Sheffer M; Horesh S; Molchadsky A; Koifman G; Shetzer Y; Goldfinger N; Rotter V; Geiger T
    Proc Natl Acad Sci U S A; 2014 May; 111(19):7006-11. PubMed ID: 24778235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube.
    Xian W; Miron A; Roh M; Semmel DR; Yassin Y; Garber J; Oliva E; Goodman A; Mehra K; Berkowitz RS; Crum CP; Quade BJ
    J Pathol; 2010 Jan; 220(1):17-23. PubMed ID: 19834951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allele-specific wild-type TP53 expression in the unaffected carrier parent of children with Li-Fraumeni syndrome.
    Buzby JS; Williams SA; Schaffer L; Head SR; Nugent DJ
    Cancer Genet; 2017 Feb; 211():9-17. PubMed ID: 28279309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unaffected Li-Fraumeni Syndrome Carrier Parent Demonstrates Allele-Specific mRNA Stabilization of Wild-Type
    Buzby JS; Williams SA; Nugent DJ
    Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The function of a heterozygous p53 mutation in a Li-Fraumeni syndrome patient.
    Li Y; Li T; Tang Y; Zhan Z; Ding L; Song L; Yu T; Yang Y; Ma J; Zhang Y; Zhou Y; Gu S; Xu M; Gao Y; Li Y
    PLoS One; 2020; 15(6):e0234262. PubMed ID: 32516327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 mutants G245S and R337H associated with the Li-Fraumeni syndrome regulate distinct metabolic pathways.
    Meneghetti BV; Wilson R; Dias CK; Cadore NA; Klamt F; Zaha A; Ferreira HB; Monteiro KM
    Biochimie; 2022 Jul; 198():141-154. PubMed ID: 35367578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.
    Plummer SJ; Santibáñez-Koref M; Kurosaki T; Liao S; Noble B; Fain PR; Anton-Culver H; Casey G
    Oncogene; 1994 Nov; 9(11):3273-80. PubMed ID: 7936651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity of Li-Fraumeni syndrome links to unequal gain-of-function effects of p53 mutations.
    Xu J; Qian J; Hu Y; Wang J; Zhou X; Chen H; Fang JY
    Sci Rep; 2014 Feb; 4():4223. PubMed ID: 24573247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome.
    Srivastava S; Tong YA; Devadas K; Zou ZQ; Sykes VW; Chen Y; Blattner WA; Pirollo K; Chang EH
    Oncogene; 1992 May; 7(5):987-91. PubMed ID: 1373881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Li-Fraumeni Syndrome-Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death.
    Choe JH; Kawase T; Xu A; Guzman A; Obradovic AZ; Low-Calle AM; Alaghebandan B; Raghavan A; Long K; Hwang PM; Schiffman JD; Zhu Y; Zhao R; Lee DF; Katz C; Prives C
    Cancer Discov; 2023 May; 13(5):1250-1273. PubMed ID: 37067901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain.
    Gu J; Kawai H; Wiederschain D; Yuan ZM
    Cancer Res; 2001 Feb; 61(4):1741-6. PubMed ID: 11245491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.
    Zhou R; Xu A; Gingold J; Strong LC; Zhao R; Lee DF
    Trends Pharmacol Sci; 2017 Oct; 38(10):908-927. PubMed ID: 28818333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Divergent control of Cav-1 expression in non-cancerous Li-Fraumeni syndrome and human cancer cell lines.
    Sherif ZA; Sultan AS
    Cancer Biol Ther; 2013 Jan; 14(1):29-38. PubMed ID: 23114650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant p53 induces Golgi tubulo-vesiculation driving a prometastatic secretome.
    Capaci V; Bascetta L; Fantuz M; Beznoussenko GV; Sommaggio R; Cancila V; Bisso A; Campaner E; Mironov AA; Wiśniewski JR; Ulloa Severino L; Scaini D; Bossi F; Lees J; Alon N; Brunga L; Malkin D; Piazza S; Collavin L; Rosato A; Bicciato S; Tripodo C; Mantovani F; Del Sal G
    Nat Commun; 2020 Aug; 11(1):3945. PubMed ID: 32770028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and characterization of two novel germ line p53 mutations in the non-LFS/non-LFL breast cancer families in Chinese population.
    Cao AY; Jin W; Shi PC; Di GH; Shen ZZ; Shao ZM
    Breast Cancer Res Treat; 2010 Jan; 119(2):295-303. PubMed ID: 19238535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis.
    Hanel W; Marchenko N; Xu S; Yu SX; Weng W; Moll U
    Cell Death Differ; 2013 Jul; 20(7):898-909. PubMed ID: 23538418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.